Prospects for Development of Induced Pluripotent Stem Cell‑Derived CAR‑Targeted Immunotherapies

Roberta Mazza, John Maher

Research output: Contribution to journalReview articlepeer-review

55 Downloads (Pure)


Technologies required to generate induced pluripotent stem cells (iPSC) were first described 15 years ago, providing a strong impetus to the field of regenerative medicine. In parallel, immunotherapy has finally emerged as a clinically meaningful
modality of cancer therapy. In particular, impressive efficacy has been achieved in patients with selected haematological malignancies using ex vivo expanded autologous T cells engineered to express chimeric antigen receptors (CARs). While
solid tumours account for over 90% of human cancer, they currently are largely refractory to this therapeutic approach. Nonetheless, given the considerable innovation taking place worldwide in the CAR field, it is likely that effective solutions
for common solid tumours will emerge in the near future. Such a development will create significant new challenges in the scalable delivery of these complex, costly and individualised therapies. CAR-engineered immune cell products that originate
from iPSCs offer the potential to generate unlimited numbers of homogeneous, standardised cell products in which multiple defined gene modification events have been introduced to ensure safety, potency and reproducibility. Here, we review some
of the emerging strategies in use to engineer CAR-expressing iPSC-derived drug products.
Original languageEnglish
Pages (from-to)70
Number of pages14
JournalArchivum Immunologiae et Therapiae Experimentalis
Publication statusPublished - 12 Dec 2021


Dive into the research topics of 'Prospects for Development of Induced Pluripotent Stem Cell‑Derived CAR‑Targeted Immunotherapies'. Together they form a unique fingerprint.

Cite this